Home Companies Catalysts Deep Dives
Donzakimig UCB1381 PHASE2
Drug Profile
ModalityMulti-specific antibody
RouteSC
Therapy AreaImmunology
Peak Sales Est$2000M
Formulations[]
Companies
UCB (ORIGINATOR)100%
Mechanism: IL-13/IL-22 inhibitor
Expert: Multi-specific antibody blocking IL-13 and IL-22
Everyday: Multi-specific antibody blocking IL-13 and IL-22
Targets: ["IL-22","IL-13"]
Programs (1)
IndicationStageKey StudyRegional Status
Atopic dermatitisPHASE2Phase 2b[]
Upcoming Catalysts (1)
Donzakimig - Atopic Dermatitis - Ph2a - Results H2 2025
Data from Supabase · Updated 2026-03-24